SCHEMBL6806201

SCHEMBL6806201

CC(=O)N[C@H]1[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)[C@H]2O)[C@@H](CO)O[C@@H]1O

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LGALS3 P17931 6/20 0.62
▸ LGALS8 O00214 1/20 0.62
▸ LGALS4 P56470 1/20 0.62
▸ MAPK1 P28482 2/20 0.56
▸ CD69 Q07108 1/20 0.49
▸ CHIA Q9BZP6 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ THRB P10828 1/20 0.48
▸ LGALS1 P09382 1/20 0.48
▸ LGALS7; LGALS7B P47929 1/20 0.48
▸ LGALS9 O00182 1/20 0.46
▸ FGF1 P05230 1/20 0.46
▸ FGF2 P09038 1/20 0.46
▸ VEGFA P15692 1/20 0.46
▸ HPSE Q9Y251 1/20 0.46
▸ AMY2A P04746 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34473199 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL6806198 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL29399861 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL19579354 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL17777302 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL18867406 1.00 LGALS3 (0.62) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL29399259 0.98 LGALS3 (0.63) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL30097961 0.97 LGALS3 (0.59) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL9398176 0.96 LGALS3 (0.66) LGALS3LGALS8LGALS4MAPK1CD69
SCHEMBL17050874 0.96 LGALS3 (0.66) LGALS3LGALS8LGALS4MAPK1CD69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058888-A1 Methods for synthesis of alpha-d-gal (1~>3) gal-containing oligosaccharides ALCHEMIA PTY LTD. (AU) 2004-03-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058888-A1 Methods for synthesis of alpha-d-gal (1~>3) gal-containing oligosaccharides B4GALT1, B3GAT3, FUT5 LGALS3 28/4885LGALS8 65/4885LGALS4 26/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback